

PERSONAL INFORMATION

Fabrizio Bianchi, PhD



📍 Lecco, Italy

📞 + [REDACTED]

✉ [REDACTED]

🌐 <https://www.cancerbiolab.com>

🔗 <https://orcid.org/0000-0001-7412-8638>

Sex: Male | Date of birth: 20/02/1977 | Nationality: Italian

Enterprise	University	EPR
☐ Management Level	☐ Full professor	☐ Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator
☐ Mid-Management Level	☐ Associate Professor	☐ Level III Researcher and Technologist
☒ Employee / worker level	☐ Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	☐ Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

WORK EXPERIENCE

from 2024 - present

Member, Basic and Translational Science Committee & Academy Mentor (IASLC)

The International Association for the Study of Lung Cancer (IASLC), Denver, USA

- The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer (<https://www.iaslc.org/basic-and-translational-science-committee>).

from 2024 - present

Member, Technical Scientific Committee (CTS - fellowship)

Italian Association for Cancer Research (AIRC) Foundation, Milan, Italy

- The Technical Scientific Committee (CTS) is the body of the Foundation, chaired by the Scientific Director, in charge of the evaluation of applications for research projects and fellowships. (<https://www.direzionescientifica.airc.it/about-us/technical-scientific-committee/>)

from 2023 - present

Board of Professors, Converging Technologies for Biomolecular Systems (TeCSBi)

University of Milan Bicocca, Milan, Italy (<https://www.btbs.unimib.it/en/research/doctoral-program-tecsbi/doctoral-board>)

from 2016 - present

Head, Cancer Biomarkers Unit

Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

- Direction of a research lab (7 members: 2 postdocs, 2 staff scientist, 3 PhD student); Principal investigator of several research projects funded by external research funding organization

from 2020 - 2025

Member of the Directive Committee and Treasurer

Italian Society of Cancer Research (SIC), Milan, Italy

Promoting cancer research in Italy (<https://cancerologia.it/consiglio-direttivo>)

from 2010 - 2016

Senior Scientist

IRCCS European Institute of Oncology, Milan, Italy

- Principal investigator of several research projects funded by external research funding organization

from 2015 - 2016

Member of the Directive Committee of Lung Cancer Program

IRCCS European Institute of Oncology, Milan, Italy

Organizing translational research activities focused on lung cancer early diagnosis and new therapies

from 2005 - 2010

Postdoctoral Fellow

IFOM – The Firc Institute for Molecular Oncology

- Principal investigator of research projects funded by external research funding organization
- Business or sector: cancer research

from 2001 - 2005

PhD Student

IFOM – The Firc Institute for Molecular Oncology

- I was involved in a research project focused on the molecular biology of lung cancer metastases and gene expression analysis by microarray technology

EDUCATION AND TRAINING

from 2002 - 2005

PhD in Molecular and Biological Sciences

University of Milan, Milan, Italy

- Cancer Biology and Molecular Biology, Microarray gene expression analysis, Cancer Biomarkers

from 1996 - 2001

Master in Science (Laurea) in Biological Sciences

University of Milan, Milan, Italy

- Molecular Biology, Biochemistry, Immunology, Protein Engineering, Biotechnology

WORK ACTIVITIES

Awards and honours

- Research fellowship from Merck Sharp & Dohme, London, UK (from 2004-2006)
- Research fellowship from the Italian Foundation for Cancer Research (FIRC), Milan, Italy (from 2001-2002)
- Research fellowship from the Italian Association for Cancer Research (AIRC), Milan, Italy (from 2002-2003)
- Research contract (Assegnista di Ricerca) from University of Milan (from 2008-2012)
- National Scientific Qualification (2023) - General Pathology and Clinical Pathology (6/A2), 1st level (Full Professor)
- National Scientific Qualification (2023) - General Pathology and Clinical Pathology (6/A2), 2nd level (Associate Professor)
- National Scientific Qualification (2025) - Molecular Biology (5/E2) 1st level (Full Professor)
- National Scientific Qualification (2025) - Molecular Biology (5/E2), 2nd level (Associate Professor)

Collaborations

- Viswam S. Nair MD MS, Associate Professor, Translational Science & Therapeutics, Public Health Sciences, Clinical Research Divisions - Fred Hutch Cancer Center (Seattle, US)
- Luis M. Montuenga, PhD, Professor of Cell Biology, Univesity of Navarra (Spain)
- Alberto Ciccia, PhD, Professor in the Department of Genetics and Development and the Herbert Irving Comprehensive Cancer Center - Columbia University (New York, US).
- Elisa Romeo, PhD, COO of CpG Diagnostics (San Diego, CA, US)
- Witold Ryzman, MD, Medical University of Gdansk, Poland
- Paolo Girotti, MD, General, Visceral and Thoracic Surgery Department, Landeskrankenhaus Feldkirch, Feldkirch, Austria
- Giovanni Bertalot, MD, Centre for Medical Sciences - CISMed, University of Trento, Trento, Italy
- Ugo Cavallaro, PhD, Unit of Gynecological Oncology Research, European Institute of Oncology IRCSS, Milano, Italy
- Tiziana Bonaldi, PhD, Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy
- Giuseppe Pelosi, MD, Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
- Giulia Veronesi, MD, Department of Thoracic Surgery, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

Editorial activity

- The International Journal of Biological Markers: Editor
- Cancers: Editor
- PeerJ: Editor
- Tumori Journal: Editor
- Frontiers in Physiology: Review Editor
- FWF Austrian Science Fund: ad hoc peer reviewer
- National Science Centre: ad hoc peer reviewer
- British Journal of Cancer (Springer Nature): ad hoc peer reviewer
- Cell Reports Medicine (Cell Press): ad hoc peer reviewer
- Clinical Chemistry (AACC): ad hoc peer reviewer
- Clinical Cancer Research (AACR journals): ad hoc peer reviewer
- Cancer Research - (AACR journal): ad hoc peer reviewer
- Cancer Research UK - Biomarker Project Award committee: ad hoc peer reviewer
- Frontiers in Oncology: ad hoc peer reviewer
- Frontiers in Genetics: ad hoc peer reviewer
- Genome Medicine (BMC, Springer Nature): ad hoc peer reviewer
- Gene (Elsevier): ad hoc peer reviewer
- Trends in Analytical Chemistry (Elsevier): ad hoc peer reviewer
- Biomedicine & Pharmacotherapy (Elsevier): ad hoc peer reviewer
- BMC bioinformatics: ad hoc peer reviewer
- Journal of Thoracic Disease: ad hoc peer reviewer
- Lancet - digital health: ad hoc peer reviewer
- Advanced Science: ad hoc peer reviewer
- Cancer communication: ad hoc peer reviewer
- Helyon: ad hoc peer reviewer
- Journal for ImmunoTherapy of cancer: ad hoc peer reviewer
- Scientific reports: ad hoc peer reviewer
- Journal for ImmunoTherapy of Cancer: ad hoc peer reviewer
- Molecular Cancer (BMC): ad hoc peer reviewer
- Journal of Hematology and Oncology (BMC): ad hoc peer reviewer
- NPJ Precision oncology: ad hoc peer reviewer

- Invited presentations**
- 2025 - IASLC 2025 Hot Topic in Basic and Translational Science Meeting: Unraveling Precancer and Early-stage Lung Cancer: From Biology to Clinical Application. Tokyo, Japan. Faculty, Invited Speaker.
 - 2025 - 10th Annual Meeting ACC 2025: NEW TECHNOLOGIES AND STRATEGIES TO FIGHT CANCER (Alleanza Contro il Cancro). Verona, Italy. Faculty, Chairman.
 - 2024 – 64th Annual Meeting of The Italian Cancer Society (SIC). Milan, Italy. Faculty, Chairman.
 - 2024 - 50th World Conference on Lung Cancer (WCLC24, San Diego CA, USA) Faculty, Invited Speaker - Poster Tour Presenter: “PT01.02.03 - Mirnome Functional Profiling of Non-Small Cell Lung Cancer Identified New Mechanisms of PD-L1 Regulation”.
 - 2024 - 50th World Conference on Lung Cancer (WCLC24, San Diego CA, USA) Faculty, Chairman of the session: “MA07 - Novel Targets to Overcome Resistance to Therapy”.
 - 2021 - 25th Gliwice Scientific Meetings - Session: “Cancer Moonshot – Early Detection of Lung Cancer”. Invited speaker: “The small world of microRNAs and their big role in Lung Cancer”.
 - 2020 - 1th Italian Society of Cancer Research (SIC) Virtual Congress: “Precision medicine: from tumor biology to clinical trials”. Chairman.
 - 2019 - 61th Italian Society of Cancer Research (SIC, EACR partner). Naples, Italy. Chairman.
 - 2019 - IASLC 2019 World Conference on Lung Cancer. Barcellona, Spain. Invited chairman and speaker.
 - 2018 - 60th Italian Society of Cancer Research (EACR partner). Milan, Italy. Invited Speaker.
 - 2015 - ELCC 2015 European Lung Cancer Conference. Geneve. Invited speaker: “Molecular markers for early detection”.
 - 2013 - 21st European conference on general thoracic surgery. Birmingham, UK. Invited speaker: “Circulating microRNAs: next-generation biomarkers for lung cancer early detection”.
 - 2012 - I-ELCAP. 27th International Conference on Screening for Lung Cancer. New York, USA. Invited speaker: “Circulating microRNAs: next-generation biomarkers for lung cancer early detection”.
 - 2012 - European Network Workshop on System Medicine. Venice, Italy. Invited speaker: “Biomarkers for lung cancer”.
 - 2009 - Deregulation of Transcription in Cancer (Keystone Symposia). Killarney, Ireland. Invited Speaker: “Global Mapping of Oncogenic Expression Signatures in Lung Adenocarcinoma”.

- Grants** **Current:**
- **Agency:** Italian Association for Cancer Research (AIRC). Investigator Grant (Id.22827). **PI:** Fabrizio Bianchi. **Title:** miRNome functional profiling of lung cancer to unveil mechanisms of resistance to immune checkpoint inhibitors. **Funding period:** 2025-2030. **Amount:** 944,000 Euro.
 - **Agency:** Italian Ministry of Health (MoH) – RF2021-12372433. **PI:** Fabrizio Bianchi. **Title:** Identification of molecular mechanisms which drive tumor cell plasticity and aggressiveness in human non-small cell lung cancer. **Funding period:** 2024 – 2027. **Amount:** 450,000 Euro.
 - **Agency:** Italian Ministry of Health (MoH) – PNRR-POC-2023-12377322. **PI (coordinator):** Fabrizio Bianchi. **Title:** TOGGLER: Theranostics fOr aGgressive Lung cancer. **Funding period:** 2024 – 2026. **Amount:** 1,000,000 Euro.
 - **Agency:** Italian Ministry of Health (MoH) – PNRR-TR1-2023-12377367. **Collaborator:** Elisa Dama (senior scientist of my lab). **Title:** Coupling multi-omics with organotypic models to unravel the pathobiology and explore vulnerabilities in low-grade serous ovarian cancer **Funding period:** 2024 – 2026. **Amount:** 990,000 Euro.
- Past:**
- **Agency:** Italian Association for Cancer Research (AIRC). Investigator Grant (Id.22827). **PI:** Fabrizio Bianchi. **Title:** microRNA expression profile of lymph node metastases: new therapeutic options to defeat lung cancer mortality. **Funding period:** 2020 – 2024. **Amount:** 860,000 Euro.
 - **Agency:** Italian Ministry of Health (MoH) – GR-2016-02363975. **PI:** Fabrizio Bianchi. **Title:** Unveil the role of cell-free circulating microRNA in lung cancer. **Funding period:** 2018 – 2021. **Amount:** 430,000 Euro.
 - **Agency:** Alliance Against Cancer (ACC) – WG Lung. **Title:** Validation of predictive biomarkers of neoadjuvant chemotherapy in NSCLC. **PI:** Fabrizio Bianchi. **Funding period:** 2020 – 2021. **Amount:** 17,000 Euro.
 - **Agency:** ERA-NET: Aligning national/regional translational cancer research programmes and activities. **PI:** Fabrizio Bianchi (Partner-PI). **Title:** Validation of multiparametric models and Circulating and imaging biomarkers to improve Lung cancer EARLY detection. **Funding period:** 2018-2021. **Amount:** 1,800,000 Euro.
 - **Agency:** Italian Association for Cancer Research (AIRC). My First AIRC Grant (MFAG 2015 Id.17568). **PI:** Fabrizio Bianchi. **Title:** Unraveling molecular signatures of chemoresistance by combined miRNA/mRNA profiling of locally advanced lung cancers. **Funding period:** 2016 – 2019. **Amount:** 222,000 Euro.
- Patents**
- Cancer Markers: the invention relates to methods of diagnosis and prognosis of cancer (WO2006037462 - 2006-04-13; US 2010/0152058 A1 – 2009-10-09).
 - A method to identify asymptomatic high-risk individuals with early-stage lung cancer by means of detecting miRNAs in biologic fluids (WO2012089630 - EP2505663 - 2012-10-03)
 - A method to identify asymptomatic high-risk individuals with early-stage lung cancer by means of detecting miRNAs in biologic fluids (WO2012089630 - EP2505663 - 2012-10-03)
 - PCT#: WO2022122994; title: PROGNOSTIC METHOD FOR AGGRESSIVE LUNG ADENOCARCINOMAS; filing date: 10.12.2021; priority#: EP20200213323
 - A miRNA-based blood test for lung cancer detection (Provisional Application - #63/726,272; filing date: 28/11/2024).

ADDITIONAL INFORMATION

Publications total number of publications in peer-review journals: 97
H index: 34 (Scopus)